Diagnosis and Screening of Neurological Disorders

Early diagnosis and proper screening of neurological disorders is the key for better prognosis and cure. Investigating the damage caused to the nervous system is extremely complicated and complex. Most of the similar symptoms happen in different disorders. There are many disorders which doesn't have definitive causes, markers, or tests, that makes a diagnosis even harder.

To confirm a neurologic condition such as brain injury, tumors, hydrocephalus, aneurysm, epilepsy or stroke, a range of neurologic tests are performed.

Sub-track

• CT scan
• Electroencephalogram (EEG
• MRI
• nerve conduction velocity
• electromyography
• Positron emission tomography
• Arteriogram
• Spinal tap
• Neurosonography
• Ultrasound

Market Analysis: Several neurological disorders, such as Multiple Sclerosis, Alzheimer's disease (AD), and Parkinson's disease, are diagnosed with neurological disorder diagnostic instruments (PD). 
Furthermore, the recent rise in the prevalence of neurological disorders is expected to drive the global neurological disease diagnostic market. 
The neurodiagnostics market is estimated to grow at a CAGR of 7.3 percent from USD 5.9 billion in 2019 to USD 8.4 billion in 2024.
The growing prevalence of neurological disorders and diseases, technological advancements, growing patient emphasis on effective and early disease diagnosis, the growing number of diagnostic centres and hospitals, and the use of biomarker profiling for disease diagnostics are all expected to drive demand for neurodiagnostics products. The global neurological biomarkers market was valued at USD 6.1 billion in 2020, with a compound annual growth rate (CAGR) of 12.9 percent predicted from 2020 to 2028. Furthermore, technological improvements are fueling market expansion by increasing the requirement for early identification of neurological illnesses.